Skip to main content

Table 1 Baseline characteristics of patients

From: Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin

Protective strategy

Dexrazoxane

Continuous infusion

Crossover

Total Number

8

11

10

Age

25–69

24–71

23–66

Sex (M/F)

3/5

7/4

3/7

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us